8-KFiled Jul 22, 8:00 PM ET

VPR Brands, LP Enters $11M Patent License Deal with JUUL Labs

$VPRB · VPR Brands, LP.

Research Summary

AI-generated summary of this SEC filing

Updated

VPR Brands, LP Enters $11M Patent License Deal with JUUL Labs

What Happened

  • VPR Brands, LP (VPRB) filed an 8-K (Item 1.01) reporting that on July 22, 2026 it entered a License and Release Agreement with JUUL Labs, Inc. The agreement settles potential disputes over U.S. Patent No. 8,205,622 B2 (the “’622 Patent”) and related patent claims in exchange for $11,000,000 paid by JUUL under an installment schedule and mutual releases by both parties.
  • Under the agreement VPRB granted JUUL and its affiliates a non-exclusive, worldwide, perpetual license (with limited exceptions) to make, sell, import, export, use and distribute Licensed Products covered by the ’622 Patent and other patent claims, subject to restrictions in the agreement.

Key Details

  • Counterparty: JUUL Labs, Inc.; Agreement date: July 22, 2026.
  • Consideration: $11,000,000 payable per an installment schedule in the agreement.
  • License scope: non-exclusive, worldwide, perpetual, irrevocable (except as set forth), non-transferable, no sublicensing right; applies only to defined “Licensed Products.”
  • Term: remains in effect until six years after the later of (a) expiration of the ’622 Patent or (b) expiration of the last Other Patent Claim; VPRB may terminate for material breach tied to payment or covenant violations.
  • VPRB intends to file the full agreement (with permitted redactions) as an exhibit to its 10-Q for the quarter ending September 30, 2026.

Why It Matters

  • The agreement provides VPRB with $11.0M in consideration and resolves potential patent disputes with JUUL, converting litigation risk into a defined cash arrangement and a licensed revenue event.
  • For investors, this clarifies the company’s intellectual property position related to the ’622 Patent and creates a contractual cash inflow; the filing does not disclose ongoing royalties or additional material financial terms beyond the $11M payment schedule.